Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 6/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.40 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21390251 | 1.00 | ATF4 (0.51) | ATF4HTR7SCN9ASCN7AKCNH2 | |
| SCHEMBL21390203 | 0.81 | ATF4 (0.49) | ATF4SCN9ASCN7AKCNH2SCN5A | |
| SCHEMBL24997259 | 0.80 | ATF4 (0.43) | ATF4KCNH2 | |
| SCHEMBL21390249 | 0.77 | ATF4 (0.63) | ATF4KCNH2 | |
| SCHEMBL23294739 | 0.77 | ATF4 (0.63) | ATF4KCNH2 | |
| SCHEMBL21384267 | 0.77 | ATF4 (0.55) | ATF4HTR7SCN9ASCN7AKCNH2 | |
| SCHEMBL23332820 | 0.77 | ATF4 (0.47) | ATF4SCN9A | |
| SCHEMBL21882365 | 0.76 | ATF4 (0.55) | ATF4HTR7SCN9ASCN7AKCNH2 | |
| SCHEMBL21384310 | 0.75 | CNR1 (0.53) | ATF4HTR7CNR1 | |
| SCHEMBL24997981 | 0.74 | ATF4 (0.40) | ATF4SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2024-05-02 | — | — | US | disclosed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2019183589-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885HTR7 4407/4885SCN9A 3136/4885 |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885HTR7 4407/4885SCN9A 3136/4885 |
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885HTR7 4407/4885SCN9A 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.